Skip to content

U-100 unit conversion

CJC-1295 No DAC (Modified GRF 1-29) calculator

Convert mass and volume to U-100 units. No dose is selected.

These are example numbers so you can see the math. Try yours. Change them to match the vial in your hand.

10U-100 units · 0.1 mL

25 mcg per unit · 2500 mcg/mL

How the calculator works, sources and review dates

CJC-1295 No DAC (Modified GRF 1-29) math uses the listed vial sizes on this card and the liquid you type. Concentration in mcg per mL is vial milligrams times 1000, divided by milliliters. A U-100 syringe has 100 marks per milliliter, so each unit is that concentration divided by 100. Example numbers so you can see the math: a 5 mg listing plus 2 mL of liquid. Change any number and the units change. Try the numbers. A research-market vial is not the same material used in a trial.

Editorial review 2026-10-15. source-curated; clinician review pending.

Units chart for listed CJC-1295 No DAC (Modified GRF 1-29) sizes

U-100 math for listed CJC-1295 No DAC (Modified GRF 1-29) sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.

Micrograms per U-100 unit (100 marks / mL)
Listed vial1 mL liquid2 mL liquid3 mL liquid
5 mg502516.7
8 mg804026.7
10 mg1005033.3

What is CJC-1295 No DAC (Modified GRF 1-29)?

Other names in the library: CJC-1295 no DAC, CJC1295 no DAC, Mod GRF 1-29, Modified GRF 1-29, CJC-1295 no DAC (10MG), CJC-1295 no DAC (5MG), CJC-1295 no DAC (Mod GRF 1-29) — 10mg (Out of stock) / Premium, CJC-1295 no DAC (Mod GRF 1-29) — 5mg / Premium. Evidence describes the named substance, not a quality certification or equivalence assessment of commercial stock. Listed sizes: 5 mg, 8 mg, 10 mg. A seller title is a listing. It does not prove the vial matches a paper.

What the evidence says

For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.

Regulatory context

Regulatory context; not efficacy evidence

No matched controlled clinical study of the exact no-DAC stock was verified in this audit.

Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.

Nonresponse. Nonresponse frequency not established in this excerpt.

Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.

Limits. Do not transfer the multi-day pharmacokinetics of CJC-1295 with DAC to Modified GRF 1-29.

Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Human report

Public no-DAC CJC1295 plus ipamorelin firsthand report

One public firsthand account; identity and clinical outcomes unverified.

Reported findings. During eight weeks of combined no-DAC CJC1295 and ipamorelin use, the author reports strength changes beginning around week four, with 5-10 lb bench/squat increases every other week, less next-day soreness and more tracker-estimated deep sleep. Slight visual body-composition changes were also reported.

Nonresponse. No formal nonresponse endpoint reported. Body-composition changes were described as modest and qualitative; the original report supplies no numerical body-composition or hormone results.

Harms. A head flush or tingling lasting about ten minutes after injection and vivid dreams were reported. The author did not describe strong hunger spikes; this does not establish their absence in other people.

Limits. Combined ipamorelin exposure, training and fasting prevent allocating changes to CJC1295 alone. No-DAC identity is named by the author; findings do not transfer to CJC1295 with DAC. Strength increments are self-reported, not independently checked training logs; tracker-estimated deep sleep is not polysomnography, and visual body composition is not measured fat loss. The post displays a deleted author account while its body remains visible. Adjacent comments, including other deleted accounts, are not automatically the same author or additional independently verified outcomes. Subjective reports supply neither causal proof nor a population response rate. Exact original publication/edit dates and preparation chemistry remain unknown. Browser rendering may be cached and the original-URL raw request returned HTTP 403.

Preparation: Named no-DAC CJC1295 plus ipamorelin; chemistry and brand unspecified. Route: Injection described; intramuscular versus subcutaneous route unspecified.

Read original source ↗

Editorial review 2026-10-15. Clinician review pending.

Human report

Public no-DAC CJC1295 plus ipamorelin adverse experience

One public firsthand account; the same visible commenter separately reports existing cardiology care. No diagnosis, measurements or clinical records verified.

Reported findings. No beneficial outcome described by this commenter. Other people's adjacent positive replies are not this author's outcome.

Nonresponse. Only two exposures were reported before the uncomfortable heart-rate rise. A benefit endpoint, formal nonresponse assessment and later course were not established.

Harms. The commenter reports resting heart rate rising beyond their comfort level; no numerical rate, ECG findings or diagnosed arrhythmia were supplied. A same-author reply says they already see a cardiologist, without stating a diagnosis.

Limits. Combined exposure prevents attribution to CJC1295 alone. Existing cardiology care is relevant self-reported context, not a verified diagnosis or a causal explanation. The adverse comment does not specify an administration route; the other report's injection route cannot be inherited. No-DAC and DAC formulations remain separate. The same-author cardiology reply is a substantive supporting source, not an additional independent report. Nearby replies about other compounds or other people are not assigned to this account. Self-selection, incomplete cardiovascular context and unverified preparation/clinical records prevent population harm estimates or proof of causation. Parent/comment timestamps remain unknown. Primary rendering may be cached; one raw primary-URL request returned HTTP 403. Supporting-reply raw retrieval was not attempted.

Preparation: Named no-DAC CJC1295 plus ipamorelin; chemistry and brand unspecified. Route: Not specified by this commenter.

Read original source ↗

Editorial review 2026-10-15. Clinician review pending.

Regulatory status, dated 2026-10-09

FDA product approval

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Compounding

not established. Legal compounding eligibility is not established here. Sale or a supplement label does not establish eligibility.

Research

source limited. No matched controlled clinical study of the exact no-DAC stock was verified in this audit.

Sport

unknown. Not individually verified against current sport rules. Check the exact ingredients with your sport authority.

How long it lasts, how you store it, listed sizes

This entry doesn’t give a duration in hours. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule.

Half-life on file: no single hour value. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule. Follow the label on the vial you hold. This page does not set a throw-away date after you add water.

Risks and mix-ups already on the record

  • Human safety for this exact preparation is incompletely characterized. A lack of reported problems does not establish safety.
  • No complete contraindication list is established for this exact preparation. Review pregnancy, allergies and existing conditions with a clinician.
  • No complete interaction study for this exact preparation is verified. Ingredient combinations are not presumed compatible.

People using PepBear often log: Exact product identity, formulation, dated label and any clinician-directed observations. Record symptoms and changes alongside other medicines, sleep and activity; observations do not establish causation.

Sources

  1. Regulatory context; not efficacy evidence · checked 2026-10-09

Questions people ask

Is CJC-1295 No DAC (Modified GRF 1-29) FDA-approved?

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Does PepBear pick an amount of CJC-1295 No DAC (Modified GRF 1-29)?

The calculator turns numbers you type into U-100 units. Trial or label amounts stay as cited facts.

How many units is a listed CJC-1295 No DAC (Modified GRF 1-29) vial after you add water?

Units = (amount in mcg ÷ (vial mg × 1000 ÷ water mL)) × 100 on a U-100 syringe. Enter the three numbers. The chart shows the same math for each listed vial size and 1, 2 or 3 mL of liquid.

Why flag amounts under 5 units?

A U-100 barrel is easy to misread below about 5 marks. That is a measuring warning. The page does not tell you to take more.

Related cards

Discuss the evidence and unresolved identity or safety questions with a licensed clinician. This entry provides no treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.